Sino Biopharmaceutical (HKG:1177) will soon submit a marketing application for a new indication of its Benmelstobart drug to China's National Medical Products Administration after it obtained written consent from the regulator, a Thursday bourse filing said.
The new indication is for the Benmelstobart injection in combination with Anlotinib Hydrochloride capsules for treating advanced alveolar soft part sarcoma (ASPS).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments